NASDAQ$TRVI
Trevi Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings ·
Briefing
TRVI Q3 2024 — $50.0M revenue
We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the section titled “Risk Factors,” that we believe could cause actual re. Trevi Therapeutics Inc reported Q3 2024 results. Net income of $36.5M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $50.0M.
- Net income: $36.5M.
- Operating income: $14K.
Headline financials
Revenue & EPS history
Trevi Therapeutics Inc · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q3 2024
+0.7%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+8.6%
Avg return
30 days after
42%
5 / 12 earnings
Positive
+8.1%
Q2 2024
Best reaction
-4.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.0% | +0.9% | -3.1% | |
| Q4 2025 | -4.5% | -3.8% | +36.1% | |
| Q3 2025 | -3.3% | -4.6% | +7.8% | |
| Q1 2025 | -0.9% | -3.1% | +6.0% | |
| Q3 2024 | +2.6% | +1.7% | -8.6% | |
| Q2 2024 | +8.1% | +4.2% | +13.9% | |
| Q1 2024 | -1.4% | -7.1% | -16.0% | |
| Q3 2023 | +0.0% | -6.0% | -16.1% | |
| Q2 2023 | +4.8% | +3.5% | +0.4% | |
| Q1 2023 | +0.0% | -2.2% | +85.9% | |
| Q3 2022 | +0.0% | +14.0% | +20.7% | |
| Q2 2022 | +0.2% | -13.1% | -23.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro